<DOC>
	<DOC>NCT00960362</DOC>
	<brief_summary>This trial is conducted in North America. The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetic and signs of bioactivity of increasing single doses of AGS-009 in patients with systemic lupus erythematosus (SLE).</brief_summary>
	<brief_title>An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Diagnosis of SLE Disease duration longer or equal to 6 months Stable, mild to moderate active SLE Receiving stable maintenance therapy Significant lupus nephritis Active central nervous system (CNS) disease Significant arterial or venous thrombosis (blood clots) within 12 months prior to dosing Active vasculitis requiring treatment Body weight over 120 kg History of cancer Infections viral: HIV, hepatitis B or C, EpsteinBarr virus (EBV), cytomegalovirus (CMV), varicella zoster virus (VZV), or herpes simplex virus (HSV1 or HSV2) tuberculosis (TB) Severe systemic microbial infections within the past 12 months prior to dosing Immunosuppressive and immune modulating therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>